
Please try another search
(Reuters) - British drugmaker GlaxoSmithKline will invest $250 million in Vir Biotechnology Inc and collaborate to develop potential treatments for COVID-19, the disease caused by the new coronavirus, the companies said on Monday.
Vir's shares jumped 35% before the bell, while GSK was up about 1%.
Drugmakers across the globe are rushing to develop a treatment or vaccine for the fast-spreading coronavirus that has killed over 68,400 people globally. There are currently no approved treatments for the disease.
The collaboration will bring Vir's monoclonal antibody platform technology and GSK's expertise in functional genomics under one umbrella.
The companies said initial focus will be to accelerate development of Vir's investigational treatments, VIR-7831 and VIR-7832, and plan to directly start with a mid-stage trial within the next three to five months.
Experts have said it could take 12 to 18 months to develop a coronavirus vaccine.
The equity investment from GSK is priced at $37.73 per Vir share, a 30% premium to the stock's Friday close.
Vir's shares, trading at $36.50 on Monday, have more than doubled in the year up to Friday's close.
GSK has so far focused on providing adjuvants, efficacy boosters that play a vital role in many vaccines, as part of its efforts to find potential vaccines against the coronavirus.
This is California-based Vir's second partnership with a major drugmaker for the development of a potential coronavirus treatment, having last month signed a letter of intent with Biogen Inc (NASDAQ:BIIB).
Gilead Sciences Inc (NASDAQ:GILD) is also testing its drug remdesivir as a potential coronavirus treatment.
Moderna Inc, which started testing its vaccine candidate in people last month, signed deals with the U.S. government in March to produce massive quantities of coronavirus vaccines.
(This story corrects premium to 30% from 10% in paragraph 7.)
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.